A Phase 1-2 ascending dose study to assess the pharmacodynamics, pharmacokinetics, and safety of HSP 130 in subjects with non metastatic breast cancer following single dose and multiple dose administration by subcutaneous injection

Trial Profile

A Phase 1-2 ascending dose study to assess the pharmacodynamics, pharmacokinetics, and safety of HSP 130 in subjects with non metastatic breast cancer following single dose and multiple dose administration by subcutaneous injection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Hospira; Pfizer
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
    • 03 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
    • 07 Sep 2017 Planned number of patients changed from 48 to 24.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top